IP Library Granted Patent US 8,809,021
Granted Patent B2
US 8,809,021 · App. 13/441,411 · Granted Aug 19, 2014

Monitoring recombinase polymerase amplification mixtures

Inventors: Niall A. Armes (Helions Bumpstead, GB); Olaf Piepenburg (Saffron Walden, GB); Catherine Jean Greenwood (Sawbridgeworth, GB)
Assignee: Alere San Diego Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,021
App. No.
13/441,411
Granted
Aug 19, 2014
Kind
B2
Abstract

A process includes providing a mixture that includes a recombinase, a single-strand binding protein, and one or more oligonucleotides; and detecting particles in the reaction mixture.

Claims (38)

1. A process comprising:

(a) providing a recombinase polymerase amplification reaction mixture comprising

a recombinase,

a single-stranded DNA binding protein (SSB), and

one or more oligonucleotides;

(b) contacting in a solution the recombinase polymerase amplification reaction mixture with a template nucleic acid;

(c) maintaining the reaction mixture under conditions that allow for the production of nucleic acid amplification products in the reaction mixture; and

(d) detecting particles associated with the nucleic acid amplification products in the reaction mixture.

2. The process of claim 1 , wherein the detecting is performed within 10 minutes of when the maintaining begins.

3. The process of claim 1 , wherein the reaction mixture comprises a crowding agent.

4. The process of claim 1 , wherein the detecting comprises determining a number or proportion of particles associated with nucleic acid amplification products.

5. The process of claim 1 , wherein the detecting comprises detecting single particles associated with two or more distinct nucleic acid amplification products.

6. The process of claim 1 , wherein the particles are about 0.5-20 μm in size.

7. The process of claim 1 , wherein the particles are detected using fluorescence from the particles.

8. The process of claim 1 , wherein the particles are detected without using fluorescence from the particles.

9. The process of claim 1 , wherein the particles comprise a first subset of particles and a second subset of particles, the first subset of particles is detected using fluorescence from the first subset of particles, and the second subset of particles are detected without using fluorescence from the second subset of particles.

10. The process of claim 3 , wherein the crowding agent comprises polyethylene glycol, polyvinyl alcohol, dextran and/or Ficoll.

11. The process of claim 3 , wherein the crowding agent comprises polyethylene glycol.

12. The process of claim 11 , wherein the polyethylene glycol is selected from the group consisting of PEG1450, PEG3000, PEG8000, PEG10000, PEG14000, PEG15000, PEG20000, PEG250000, PEG30000, PEG35000, PEG40000 and combinations thereof.

13. The process of claim 3 , wherein the crowding agent is present in the mixture at a concentration between 1 to 12% by weight or by volume of the mixture.

14. The process of claim 1 , wherein the recombinase comprises a RecA or UvsX protein.

15. The process of claim 1 , wherein the single-stranded DNA binding protein (SSB) comprises a prokaryotic SSB protein or a SSB protein derived from a myoviridae phage.

16. The process of claim 1 , wherein at least one of the one or more oligonucleotides comprises a detectable label.

17. The process of claim 1 , wherein the particles comprise one or more of the recombinase, the single-strand binding protein (SSB), and at least one of the one or more oligonucleotides.

18. The process of claim 1 , wherein the mixture further comprises one or more of: a DNA polymerase, a recombinase loading protein, dNTPs or a mixture of dNTPs and ddNTPs, a reducing agent, creatine kinase, a nuclease, a nucleic acid probe, and a reverse transcriptase.

19. The process of claim 1 , wherein the particles are about 1-10 μm in size.

20. The process of claim 1 , wherein detecting particles in the mixture comprises the use of microscopy.

21. The process of claim 1 , wherein detecting particles in the mixture comprises the use of flow cytometry.

22. The process of claim 1 , wherein the particles comprise one or more of the recombinase, the single-strand binding protein, at least one of the one or more oligonucleotides, and a template nucleic acid.

23. The process of claim 1 , wherein the detecting comprises determining a number or proportion of particles which are not associated with nucleic acid amplification products.

24. The process of claim 20 , further comprising the use of a camera.

25. The process of claim 21 , further comprising the use of a camera.

26. The process of claim 1 , wherein detecting particles comprises the use of a camera.

27. The process of claim 3 , wherein the crowding agent is present at a concentration of between 2% and 8%.

28. The process of claim 27 , wherein the crowding agent is present at a concentration of between 4% and 5.5%.

29. The method of claim 15 , wherein the single-stranded DNA binding protein (SSB) comprises a T4 gp32 protein or a Rb69 gp32 protein.

30. The method of claim 15 , wherein the single-stranded DNA binding protein (SSB) comprises an E. coli SSB.

31. The process of claim 11 , wherein the polyethylene glycol is a PEG compound with molecular weight between 15,000 and 20,000 daltons.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2012
From: ARMES, NIALL A.; PIEPENBURG, OLAF; GREENWOOD, CATHERINE JEAN
To: ALERE SAN DIEGO, INC.
Reel/Frame 028459/0946 →
Continuity (2)
Provisional Application 61472919 · Apr 7, 2011
Related Publication 20120258456A1 · Oct 11, 2012